India set for cheap Ozempic alternatives, regulators issue safety alert

As affordable generic weight-loss drugs enter the Indian market, CDSCO has warned against self-medication and misleading advertisements. Regulators stress medical supervision, highlighting potential health risks and enforcing stricter rules for pharmaceutical companies launching these drugs.

Hyderabad: Think twice before you pop the ‘miracle’ weight-loss pill or use a self-administered injection, which are set to become available in affordable generic forms across the country in the coming days. With such medications set to get readily available, drug regulators have issued a stark warning ‘do not self-administer therapies without professional medical supervision’ to those looking to lose weight.

The Central Drugs Standard Control Organisation (CDSCO) recently issued a high-priority advisory to individuals to not get swayed by influencer marketing. It is described as a violation of the Drugs and Cosmetics Act to utilise social media personalities to launch ‘surrogate platforms’ advertising that claim ‘guaranteed results’ or ‘transformation journeys’.

---

The notices from regulatory authorities have come at a time when the Indian healthcare market prepares for the launch of generic versions of Ozemipic and Wegovy. The licensing exclusivity for semaglutide (marketed as Ozempic and Wegovy) ends in India on March 20, 2026, triggering a massive shift in the Indian pharma market.

Over 50 Indian pharmaceutical brands are poised to launch generic versions as early as March 21. Almost all the major players, including Sun Pharma (Noveltreat), Dr Reddy’s (Obeda/Diagluton), Zydus (Semaglyn), Lupin (Semalup), and Alkem (Semaglide), have already secured or are awaiting final clearances.

While Novo Nordisk used to sell Ozempic for Rs 15,000 to Rs 25,000 per month, the generic versions will cost anywhere between Rs 3,000 and Rs 5,000, a drop of 50 per cent to 80 per cent.

The drug regulators have also said they have already observed a surge in “disease awareness” campaigns that indirectly promote these prescription-only drugs, also known as GLP-1 receptor agonists, the class of drugs including the global blockbuster semaglutide.

Authorities have strictly prohibited any communication that ‘guarantees’ weight loss or suggests that these drugs are a standalone solution, bypassing the need for diet and exercise.

The CDSCO reminded the public that these are Schedule G prescription drugs, and self-medication or demand induced by social media can lead to severe health risks, including acute pancreatitis and gastrointestinal complications.

To prevent a mad rush to procure such drugs, after getting influenced by aggressive marketing during this transition, the CDSCO has mandated that all new generic launches must include a Risk Management Plan (RMP) and clear patient information leaflets with dedicated complaint numbers.

Medical experts urge caution, with the CDSCO emphasising that obesity is a chronic metabolic condition, not a cosmetic issue to be solved by a reel on social media. Patients were advised to consult only registered medical practitioners and ignore any advertisement that downplays lifestyle modifications or promises an “easy fix.”